Eledon Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGEledon Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 90), indicating clear outperformance against the broad market. Earnings growth of 28% provides fundamental context to the price action. However, price is extended 21% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.59 | +5.93% | ABOVE |
| 50 SMA | $3.13 | +21.43% | ABOVE |
| 100 SMA | $2.53 | +50.17% | ABOVE |
| 150 SMA | $2.55 | +48.87% | ABOVE |
| 200 SMA | $2.61 | +45.71% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ELDN in an uptrend right now?
ELDN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ELDN overbought or oversold?
ELDN's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is ELDN outperforming the market?
ELDN has a Relative Strength (RS) Rating of 90 out of 99. Yes, ELDN is a market leader, outperforming 90% of all stocks over the past 12 months.
Where is ELDN in its 52-week range?
ELDN is trading at $3.80, which is 83% of its 52-week high ($4.60) and 75% above its 52-week low ($1.35).
How volatile is ELDN?
ELDN has a Beta of 1.92 and 52-week volatility of 90%. It's more volatile than the S&P 500 - expect bigger swings.